BioArctic AB’s partner Eisai presented new data for Lecanemab back-up, an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, at the Alzheimer’s Association International Conference (AAIC) held in San Diego, California and virtually July 31 through August 4, 2022.
Eisai presented lecanemab data and research in one oral and eight poster presentations at the meeting. Highlights included new data on a subcutaneous formulation of lecanemab. The new data has been used to define the appropriate subcutaneous dosing now being further evaluated in the Phase 3 Clarity AD open label extension study. A further highlight was the presentation of a modeling simulation of the impact of ApoE4 genotype on the incidence of amyloid-related imaging abnormalities – edema/effusion (ARIA-E) – in subjects treated with lecanemab. The modeling predicted incidence on ARIA-E in ApoE4 carriers (homo- and heterozygotes) and non-carriers, and corresponds well with what has been observed in the Phase 2b core and open label extension studies.